STAT Plus: Argenx antibody drug improves symptoms in patients with myasthenia gravis
Argenx, a Belgian drug maker, said Tuesday that its experimental medicine improved the symptoms of…
Category: biotechnology
Listen: Moderna’s scant coronavirus data, the plight of the day trader, and the world’s dependence on biotech
When is a press release worth $5 billion? Can biotech stocks replace sports? And how…
STAT Plus: Kadmon to seek FDA approval of drug targeting graft-versus-host disease following positive study outcome
Kadmon Holdings, the New York-based biotech, said Thursday that its experimental pill for chronic graft-versus-host…
STAT Plus: A secret coup and a ‘poison pill’ have frozen shares of a biotech in the race for a Covid-19 vaccine
Moderna’s work on a vaccine for coronavirus has made its founders into paper billionaires. Gilead…
STAT Plus: Pharmalittle: Experts say wait-and-see about Moderna’s Covid-19 vaccine; J&J will stop selling talc products in the U.S.
Hello, everyone, and welcome to the middle of the week. Time flies when you are…
STAT Plus: Moderna carries a big-boy market valuation now, so it shouldn’t act like a biotech penny stock
Some additional thoughts and comments on Moderna, its coronavirus vaccine, the stock’s valuation and Monday…
Gilead ups its donation of the Covid-19 drug remdesivir for U.S. hospitals
Gilead Sciences, the drug company behind the experimental Covid-19 therapy remdesivir, has upped the number…
STAT Plus: Alexion becomes latest company to face pressure to sell from activist investor
When Elliott Management knocks, it’s difficult not to answer the door. The New York investment firm led…
STAT Plus: Pfizer says efficacy of its Duchenne gene therapy outweighs side effects
Pfizer’s experimental gene therapy to treat Duchenne muscular dystrophy appeared to improve muscle function in…
Biotech’s new chief lobbyist says she’s a social justice advocate. Will the industry walk the walk?
WASHINGTON — Michelle McMurry-Heath doesn’t talk about biotech the way her peers do. Where other…
STAT Plus: Amgen’s KRAS-blocking drug shows small improvement in colon cancer response
Amgen’s experimental KRAS-blocking drug is showing a modest improvement in response rates for patients with…
STAT Plus: Roche’s novel checkpoint inhibitor delivers mixed results in new lung cancer study
Roche on Wednesday said a two-drug combination that includes a novel but still experimental checkpoint-blocking…
STAT Plus: Some blood cancer patients see remission with Allogene’s off-the-shelf CAR-T cells, early data show
Allogene on Wednesday released the first data on tumor responses to its off-the-shelf CAR-T cell…
STAT Plus: FDA refuses application for cell therapy from Bristol and Bluebird, dealing both a major setback
The Food and Drug Administration refused to even consider an application to approve a new…
.jpg)
STAT Plus: Trump administration proposes a dramatic payment boost for CAR-T treatments under Medicare
WASHINGTON — The Centers for Medicare and Medicaid Services proposed a major payment bump for…
STAT Plus: With hopes running high for Moderna’s coronavirus vaccine, the stock’s value requires an almost mythical leap of faith
Moderna is moving at unprecedented speed to develop a vaccine to prevent infection from the…
French drug maker Genfit says NASH drug fails late-stage clinical trial
French drug maker Genfit said Monday that its lead drug, elafibranor, failed to improve outcomes…
STAT Plus: Prominent Broad Institute scientist leaves to lead R&D at Genentech
A star scientist in the world of single-cell genomics and computational biology is leaving academia…
.jpg)
STAT Plus: Results indicate MyoKardia drug is a ‘potential game changer’ for heart condition
An experimental drug to treat an inherited, progressive heart disease clearly improved the symptoms of…
STAT Plus: CytoDyn says lead HIV drug was not filed for FDA approval, as previously claimed
CytoDyn CEO Nader Pourhassan is already under fire for the timing of lucrative sales of…
STAT Plus: CytoDyn CEO made $12M from his stock sale, and his explanation raises more questions
CytoDyn chief executive Nader Pourhassan’s lucrative sale of company stock was confirmed in a regulatory…
STAT Plus: Akebia’s experimental pill meets anemia, heart-safety goals in two late-stage clinical trials
Akebia Therapeutics said Tuesday that its experimental anemia pill achieved the primary efficacy and heart-safety…
STAT Plus: With remdesivir, Gilead finds itself at strategic crossroads, with its reputation (and far more) at stake
Never in modern times have such high hopes for millions of lives rested on one…
STAT Plus: Without showing any data, CytoDyn touts treatment for Covid-19 as winner — while its CEO sells stock
While Nader Pourhassan, the chief executive of drug maker CytoDyn, filed his intention to sell…
STAT Plus: Covid-19 is forcing smaller biotechs to cut spending and change financing plans
The Covid-19 pandemic is taking a harsh toll on small biotech companies, many of which…
Gilead CEO: We’re going to make sure that access is not an issue with remdesivir
On Wednesday Gilead Sciences, best known as a maker of HIV medicines, sent out a…
STAT Plus: Patients, drug makers grapple with how to continue cancer trials during the coronavirus
The coronavirus pandemic has thrown a wrench into plans for hundreds of clinical trials seeking…
STAT Plus: For the first time, a blood test helped doctors find and treat cancers in seemingly healthy people
For the first time, doctors have used the results of a liquid biopsy test to…
STAT Plus: Off-the-shelf CAR-T therapy helps leukemia patients in a small, first-in-human trial
Scientists have created the first off-the-shelf CAR-T cells for a deadly form of adult leukemia,…
STAT Plus: New type of checkpoint inhibitor offers early promise against tumors, but will it last?
A new type of checkpoint inhibitor from an Israeli biotech company called Compugen is showing…
STAT Plus: Custom cell therapy shrinks lung tumors, seeding hope for a new cancer treatment
Tumors shrank in one quarter of patients with advanced lung cancer who received a bespoke…
STAT Plus: The coronavirus pandemic could shrink some biotech startup valuations
Determining a private company’s value means estimating how and when it might be able to…
STAT Plus: Sanofi MS drug reduced brain lesions in preliminary study
An experimental multiple sclerosis pill the drug giant Sanofi has touted as one of its…
STAT Plus: It started with a rumor. Now data show a drug is effective against graft-versus-host disease
Cancer patients inherit brand-new immune systems after undergoing bone marrow transplants. Though this intensive therapy…
Immunomedics wins FDA approval for new drug to treat aggressive form of breast cancer
Immunomedics secured U.S. approval on Wednesday for a new drug to treat women with a…
STAT Plus: Biogen delays Alzheimer’s drug filing to FDA, citing Covid-19, complexity of data analysis
Biogen said Wednesday that the submission of a U.S. marketing application for its Alzheimer’s drug…
People are dying from coronavirus because we’re not fast enough at clinical research
When medical historians look back at the Covid-19 pandemic, they will reckon with how the…
STAT Plus: On a 180-person video chat, biotech executives share the best ways do business amid the coronavirus
Given the hour — 4:30 a.m. in California, 7:30 a.m. in Boston — no one…
STAT Plus: Biogen execs have been quiet since Covid-19 spread through the biotech. The silence ends Wednesday
Do they go with a Covid-19 question? Or one about aducanumab? Maybe a combination of…
STAT Plus: Aytu Bioscience capitalizes on coronavirus antibody test demand, but the good times won’t last
A pivot towards reselling Chinese-made coronavirus antibody tests in the U.S. has transformed tiny Aytu…
Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment
A Chicago hospital treating severe Covid-19 patients with Gilead Sciences’ antiviral medicine remdesivir in a…
STAT Plus: This cancer company is biotech’s most volatile non-Covid-19 stock
In 2020, billions of dollars have been created and erased by speculation over which companies…
STAT Plus: Athersys pivots a stem cell therapy to Covid-19, but prior data offer little confidence
Athersys is confident its experimental stem cell therapy has the potential to help patients with the…
STAT Plus: Blackstone Group invests up to $2 billion in Alnylam, a big bet on the Cambridge biotech
The private equity firm Blackstone Group is investing up to $2 billion in Alnylam Pharmaceuticals,…
STAT Plus: Biotech in the time of coronavirus: The return of mergers, acquisitions, and deals
Seeing the Easter Bunny wear a mask was weird. Greetings and welcome to another semi-regular…
STAT Plus: How will the pandemic shape biotech in the months ahead? An industry analyst weighs in
The biopharma industry is racing to respond to the novel coronavirus pandemic. But the industry…
The coronavirus sneaks into cells through a key receptor. Could targeting it lead to a treatment?
Nearly 20 years ago, when a different coronavirus struck, Michael Farzan and his team figured…
Listen: Privacy in a pandemic, biopharma’s big opportunity, and Shkreli’s plea for a break
Can the drug industry win over Americans? Will the pandemic put an end to privacy?…
STAT Plus: Biotech in the time of coronavirus: Pondering the future of ‘JPM Week’
I logged into a Zoom meeting wearing a fuzzy robe. Greetings and welcome to another…
Data for Gilead’s potential coronavirus therapy are coming soon. Here’s what you need to know
This month, the world should get the first results from a clinical trial testing the…